Contact | Sitemap | Search:

Luminor leads Human Connection HR financing

Singapore - 30th June 2015 - Human Connection HR Pte Ltd (HCHR) is a leading player in the human resource supply industry in Malaysia. HCHR was founded by Datin Sri Rosmawini Abdullah in 2003 and provides a one-stop solution for companies requiring foreign workers in the manufacturing, food & beverage and cleaning services industries. Foreign labour has been a cornerstone in Malaysia's economic growth story and its demand continues to grow in tandem with the country's economic trajectory. Luminor Pacific Fund 2 was the lead investor in HCHR's pre-IPO round.


ENRA Group Bhd appoints Shamsul as director

Kuala Lumpur - 15th June 2015 - The ENRA Group announced the appointment of Tan Sri Shamsul Azhar Abbas onto its board of directors. Tan Sri Shamsul was, until March 31st 2015, the President and CEO of PETRONAS, the Malaysian national oil & gas (O&G) company. Luminor Pacific Fund 1 gained exposure into the ENRA Group in December 2014 via Amira Properties Sdn Bhd and Accentvest Sdn Bhd, whose principals are Datuk Kamaluddin Abdullah and Datuk Maslin Junid respectively. Datuk Kamaluddin and Datuk Maslin, both experienced and successful O&G entrepreneurs, subsequently took over ENRA Group (formerly known as Perduren Bhd) by indirectly acquiring a 69.3% stake for RM149.6m and subsequently launching a general offer. Tan Sri Shamsul's announcement follows other recent ENRA board appointments -notably, Datuk Ali bin Abdul Kadir (former Chairman of Malaysia's Securities Commission) and Datuk Anuar bin Ahmad (former PETRONAS board member).


Luminor leads Viking financing

Singapore - 15th October 2014 - Luminor Pacific Fund 1 was the lead investor in Viking LR1 Pte Ltd (the "Company")'s S$12.5m convertible bond financing. Viking LR1 is a subsidiary of Viking Asset Management Pte Ltd, the investment arm of Viking Offshore & Marine Ltd, an SGX-listed company. The Company's core business is the ownership and charter of oil and gas assets worldwide.


Aqua Expedition launches the Aqua Mekong

Singapore - 10th October 2014 - Luminor Capital is pleased to announce the launch of the Aqua Mekong, a luxury river cruise boat custom built to sail the Mekong River in elegance and unsurpassed luxury. Working with Italian-American entrepreneur, Francesco Galli Zugaro, Luminor Capital funded the build and fit out of the state of the art vessel through its investment in Aqua Expedition. The Aqua Mekong joins two existing luxury boats, the Aqua Amazon and Aqua Aria, which sail the Amazon River.

The Aqua Mekong's 20 suites have each panoramic floor-to-ceiling views. Cuisine is by award-winning chef, David Thompson, from the Nahm Restaurant in Bangkok. The observation deck is home to sunbeds, shaded salas, spa treatment rooms, a screening room and outdoor plunge pool with private cabanas. Daily excursions to temples, markets, villages and French colonial homes are escorted by the ship's expert private guides aboard the Aqua Mekong's four launch boats, and passengers have the use of the ship's 10 on-board bicycles.

"We are delighted to be part of the journey in bringing the visions of glamour and romance to cruising on the majestic Mekong River" says, Lawrence Chin, Executive Director of Investment at Luminor Capital. "The Aqua Mekong allows the discerning client to savour an experiential journey on the Mekong in style and class".



Terratech successfully completes IPO

Singapore - 31st July 2014 - Terratech Ltd successfully listed on the Catalist board of the SGX on 29th July 2014. The company sold 108.7 million shares at a price of S$0.23 and valued the company's market capitalization at S$141m.


Luminor leads ayondo financing

Singapore - 30th July 2014 - Luminor Pacific Fund 1 was the lead investor for ayondo Asia Pte Ltd's Convertible Bond Financing round. This is the second investment in the ayondo group for Luminor, having financed ayondo's restructuring and expansion earlier this year via a CB into ayondo Holdings AG, Switzerland. ayondo is a fore-runner in new technologies and high growth business models that can increase efficiency in the banking sector. It is one of the leading Social Trading platforms in Europe and was listed as one of the top 50 financial technology companies in 2013 by FinTech.


QT Vascular successfully completes IPO

Singapore - 2nd May 2014 - QT Vascular Ltd successfully listed on the Catalist board of the SGX on 29th April 2014. The company placed out 196.4m new shares at S$0.28 a piece, raising S$55m in proceeds. The market capitalization of the company was S$212m at time of listing. Luminor's first investment in Quattro Vascular (which eventually became QT Vascular following a merger with its parent, TriReme Medical Inc) was in 2010, and ultimately participated in a total of 4 financing rounds.


Launch of the Luminor Pacific Fund 2

Singapore - 1st September 2013 - Luminor Capital Pte Ltd, a Singapore based Private Equity Advisory Firm, today announced the launch of the Luminor Pacific 2 Fund. The Fund's focus will be mainly the Asia Pacific region, and will invest into promising companies in the Healthcare, Resources, Consumer, Lifestyle and Infrastructure sectors. The Fund's investors will primarily be overseas applicants for permanent residence in Singapore under the Singapore government's Global Investor Programme or GIP.


Luminor leads Aqua Expeditions financing

Singapore - 6th February 2013 - Luminor Pacific Fund 1 was the lead investor for Aqua Expedition Pte Ltd's S$9.8m Series A and Convertible Bond financing. Aqua Expeditions is a luxury river cruise operator with operations in South America and Asia. It was the first adventure travel company to introduce 5-star luxury cruises on the Amazon River in Peru offering cruises on custom-built boats with wildlife viewing and shore excursions into the Amazon rainforest and jungle. It will launch Asian cruises starting with the Mekong in 2014.


Luminor leads Terratech financing

Singapore - 16th November 2012 - Luminor Pacific Fund 1 was the lead investor for Terratech Resources Pte Ltd's S$15m Convertible Bond financing round. Terratech is a subsidiary of an SGX listed company, Tritech Group Ltd, and it owns one of the largest marble mining resources in SE Asia located at Gua Musang, Kelantan, Malaysia.


Luminor consortium wins SPRING's Biomedical Sciences Accelerator programme

Singapore - 9th March 2012 - Luminor Capital is pleased to announce that a partnership it has formed with Three Arch Partners, Emerald Medical Services and Dr Eitan Konstantino has been appointed as one of the two Biomedical Sciences Accelerators (BSA's) under a new S$40m government programme designed to stimulate the growth of the medical device industry in Singapore. The new partnership will be known as Singapore MedTech Accelerator (SMA).

As part of the Singapore government's Research, Innovation and Enterprise 2015 plan, the BSA will be used to fund early-stage Singapore-based medical technology companies. The fund is managed by SPRING SEEDS Capital, a wholly-owned subsidiary of SPRING Singapore.

The partners of SMA are a committed group of industry leaders with diverse experience in investments, creating and operating companies, product development & commercialisation, high volume manufacturing, quality and regulatory. It has a strong execution track record in Singapore and intends to build a strong portfolio of companies which will solve real clinical problems. Dr Eitan Konstantino said: "We share the government's vision of making Singapore an international hub for medical technologies. Singapore's business friendly environment, strategic location, highly educated talent pool and an excellent infrastructure will help Singapore become the "Silicon Valley of the East."


About Three Arch Partners

Three Arch Partners is a healthcare-only fund based in Portola Valley, California, USA. It has raised 5 funds, totaling over US$1bn, and has internally incubated over a dozen start-ups. Notable exits include Perclose (acquired by Abbott), GSI (Tyco), Biopsys Medical (J&J), Anneurx (Medtronic), Confluent (Covidien), Cohesion (Angiotech) and Reliant (Thermage). www.threearchpartners.com


About Emerald Medical Services

Emerald Medical Services is a Singapore-based company providing engineering and manufacturing services to the local and global medical device industry. the company was founded by Steve Wiesner previously the General Manager of Avalon Medical Services.


About Eitan Konstantino

Dr Eitan Konstantino is the founder & CEO of TriReme Medical Inc. and Trireme Singapore Pte Ltd which develop and sell innovative next generation percutaneous devices for the treatment of complex coronary and peripheral arterial disease. Dr. Konstantino co-founded AngioScore Inc. (profitable) and Quattro Vascular Pte Ltd, (revenue stage) and was the CEO of Advanced Stent Technology (acquired). He is the Co-Chairman of the ASTM Cardiovascular Standards Task Force in the US. www.trirememedical.com



Quattro Vascular announces FDA approval

Singapore - Singapore - 22nd December 2011 - Quattro Vascular Pte Ltd (Quattro Vascular), developer of next generation percutaneous technologies for the treatment of peripheral artery disease (PAD) announced today that its Chocolate PTA balloon catheter (Chocolate), has received FDA clearance to market the product in the US. The product is distributed in the US by TriReme Medical, Inc. PAD is an obstruction of the blood flow in the peripheral arteries, most commonly in the arteries of the pelvis and legs. Left untreated, it can lead to chronic pain, significant limitations in the ability to walk or move, decreased quality of life, amputation and even death. Developed in Singapore in collaboration with TriReme Medical, Quattro Vascular's first product, Chocolate is a highly differentiated angioplasty catheter designed for a better treatment of PAD.


Luminor Capital appoints Dr Lawrence Chin as Executive Director, Investments

Singapore - 25th September 2011 - Luminor Capital Pte Ltd (Luminor), a Singapore-based private equity advisory firm, today announced the appointment of Dr Lawrence Chin as Executive Director, Investments and to its Investment Committee. Dr Chin was previously Senior Vice President of Investments for Bio*One Capital, a dedicated US$750m investment fund of the Economic Development Board (EDB) in Singapore. He was with Bio*One for 10 years, working in both Singapore and the US, and was latterly responsible for managing all Bio*One's equity investments globally across all sectors and asset classes. Dr Chin is a physician by background, graduating MBBS from the University of Western Australia and also holds an MBA.

"We are honoured to have Lawrence join us", said Dr Foo Fatt Kah, Luminor's Managing Director and co-founder. "His impressive track record, international experience in equity investments, strategic management and business development will be key in fulfilling Luminor's goal of nurturing promising companies and backing entrepreneurs of the future. This will enhance our Fund's performance and thus good news for our investors."


Luminor leads TriReme Medical Financing

Singapore - 3rd August 2011 - Luminor Pacific Fund 1 was the lead investor for TriReme Medical Pte Ltd's Convertible Bond financing. The Company is the Singapore subsidiary of TriReme Medical Inc (which is located in Pleasanton, CA). The Company develops next generation percutaneous devices for the treatment of coronary and peripheral vascular disease. Its novel balloon and stent therapies are specifically designed for the large, unmet clinical needs in the complex coronary and peripheral artery disease markets.


Luminor leads Quattro Vascular Series B

Singapore - 12th June 2011 - Luminor Pacific Fund 1 was the lead investor for Quattro Vascular Pte Ltd's Series B financing round. Quattro Vascular was founded by Dr Eitan Konstantino and develops next generation percutaneous technologies for the treatment of peripheral and coronary vascular disease. The Company's novel minimal injury angioplasty therapy is specifically designed for the large, unmet clinical needs in the complex peripheral and coronary artery disease markets.


Quattro Vascular announces CE Mark Approval

Singapore - 17th January 2011 - Quattro Vascular Pte Ltd, developer of next generation percutaneous technologies for the treatment of peripheral artery disease (PAD) announced today that its flagship product, the Chocolate PTA balloon catheter (Chocolate), has received CE Mark approval. Chocolate, Quattro Vascular's first product, is a highly differentiated angioplasty catheter featuring compartmental, modulated inflation with pillow effects. Its unique advanced design is intended to minimize vascular overstretch and thus reduces injury during angioplasty procedures. In addition, Chocolate's innovative shaft technology consists of a braided shaft and an atraumatic tapered tip designed for greater push performance. Chocolate was developed for the treatment of complex lesions and represents the next generation in treatments of PAD.


Thomson Resources successfully completes IPO on ASX

Singapore - 17th December 2010 - Thomson Resources Ltd (TMZ.AX) today announced that the Company has successfully completed an Initial Public Offering ("IPO"), raising $4.6 million through the placement of 22,859,500 shares at 20c per share. Thomson is now fully funded to progress its exploration program over a range of targets at its dominant 6,000 km2 tenement holding in the Thomson Fold Belt in Northern NSW. The offer, which closed on 8 December, 2010, was strongly supported by institutional and retail shareholders, and also received a strong response from shareholders in founding ASX listed companies, Minotaur Exploration Limited (ASX: MEP) and Platsearch NL (ASX: PTS) to take up their priority entitlements. The capital raised will underpin an aggressive drilling program due to commence in early 2011 on its portfolio of tenements and pre-defined targets in the highly prospective and under-explored Thomson Fold Belt region.


Luminor leads Quattro Vascular Series A

Singapore - 12th October 2010 - Luminor Pacific Fund 1 was the lead investor for Quattro Vascular Pte Ltd's Series A financing round. Quattro Vascular was founded by Dr Eitan Konstantino and develops next generation percutaneous technologies for the treatment of peripheral and coronary vascular disease. The Company's novel minimal injury angioplasty therapy is specifically designed for the large, unmet clinical needs in the complex peripheral and coronary artery disease markets. Luminor's Managing Director, Dr Foo Fatt Kah joins the Quattro board post-financing.


Silver City Minerals Ltd completes pre-IPO financing round

Singapore - 2nd November 2009 - Luminor Capital completed Silver City Minerals' pre-IPO financing round with sophisticated investors in Singapore at 11cts per share. Silver City Minerals Limited (SCI) is a base and precious metal explorer focused on the Broken Hill District of western New South Wales, Australia. It takes its name from the famous Silver City of Broken Hill, home of one of the world's largest natural accumulations of silver, lead and zinc; the Broken Hill Deposit. SCI was established in May 2008 to explore specifically in the District where it controls 17 exploration tenements through various Sale and Joint Venture agreements.It has a portfolio of highly prospective ground with drill-ready targets focused on high grade gold, silver and base-metals, and a pipeline of prospects moving toward the drill assessment stage. The Company's objective is to increase shareholder wealth through capital growth and dividends, by advancing projects from exploration discovery, through development into profitable operating mines.


Thomson Resources Ltd completes pre-IPO financing round

Singapore - 30th October 2009 - Luminor Capital completed Thomson Resources' pre-IPO financing with sophisticated investors in Singapore at 10cts per share. Thomson Resources Ltd is an Australian-based exploration company focused on the discovery and development of high quality mineral deposits within the Thomson Fold Belt of northern NSW. The company was incorporated in July 2009 with major shareholders being 2 Australian listed companies, Minotaur Exploration Ltd (ASX:MEP) and Platsearch NL (ASX:PTS). All TMZ exploration tenements lie within the Thomson Fold Belt, a region of deformed and intruded sediments and volcanics thought to be the under-cover, unexplored northern extension of one of Australia's premier metalliferous mining districts, the Lachlan Fold Belt. The belt has excellent exploration potential for large, high grade metal deposits, particularly Cobar-type (copper, gold, lead, zinc, silver).


Launch of the Luminor Pacific Fund 1

Singapore - 21st March 2009 - Luminor Capital Pte Ltd, a Singapore based Private Equity Advisory Firm, today announced the launch of the Luminor Pacific 1 Fund. The Fund's focus will be the Asia Pacific region (including Australia), and it will invest into 3 sectors, namely, Resources, Renewable Energy and Recombinant Technology (or biotechnology). The Fund will primarily target overseas applicants for permanent residence in Singapore under the Singapore government's Global Investor Programme or GIP. Luminor Capital also reported that it has applied for inclusion into the GIP scheme earlier in the year.


Luminor Pacific Fund 1 receives GIP approval

Singapore - 3rd December 2009 - Luminor Pacific Fund 1 today announced that it has received its approval and inclusion into Singapore's Global Investor Programme, or GIP, from Contact Singapore. The Fund is one of 13 eligible funds under this scheme.

The GIP is part of a program to attract talented individuals to live, invest and work in Singapore. Eligibility for the GIP scheme includes individuals with a business or entrepreneurial background. Approved applicants can opt to invest in a local business in certain designated sectors or invest into a GIP approved private equity fund. The GIP is administered by Contact Singapore, an alliance between Singapore's Economic Development Board and Ministry of Manpower. Its objective is to attract global talent to invest, live and work in Singapore. Contact Singapore will work with Luminor Capital as a one-stop centre to facilitate the interests of potential permanent residents (PR) investors in Singapore.


Latest News


Contact Us

SINGAPORE
8 Marina Boulevard
Marina Bay Financial Centre
#13-02 Tower 1
Singapore 018981

About Us | Funds | Team | Investment Approach | Portfolio | News | Contact Us

Luminor Capital, All Rights Reserved © 2017